Anti-LEG8 antibody
Specifications
| Product Cat#: | AB-07-1863 |
| Product type: | Primary antibody |
| Antigen: | LEG8 |
| Immunogen: | The antiserum was produced against synthesized peptide derived from internal of human |
| LEG8. | |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:500-1:2500); Immunohistochemistry (1:50-1:100); ELISA (1:20000) |
| Reactivity: | Human, Mouse |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Concentration: | 1 mg/ml |
| Purity: | Antigen affinity chromatography |
| Storage: | Aliquot and freeze at -20°C. Avoid multiple freeze/thaw cycles. |
| Alternative names: | Galectin-8, Gal-8, Prostate carcinoma tumor antigen 1, PCTA-1, Po66 carbohydrate-binding protein, Po66-CBP, LGALS8 |
Target information
Beta-galactoside-binding lectin that acts as a sensor of membrane damage caused by infection and restricts the proliferation of infecting pathogens by targeting them for autophagy (PubMed:22246324, PubMed:28077878). Detects membrane rupture by binding beta-galactoside ligands located on the lumenal side of the endosome membrane; these ligands becoming exposed to the cytoplasm following rupture (PubMed:22246324, PubMed:28077878). Restricts infection by initiating autophagy via interaction with CALCOCO2/NDP52 (PubMed:22246324, PubMed:28077878). Required to restrict infection of bacterial invasion such as S.typhimurium (PubMed:22246324). Also required to restrict infection of Picornaviridae viruses (PubMed:28077878). Has a marked preference for 3′-O-sialylated and 3′-O-sulfated glycans (PubMed:21288902).
Provider
Erpantech Laboratory
